Home ›
Sarcoma Trials ›
NCT05617859
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
Trial Details
NCT ID NCT05617859
Phase PHASE2
Sponsor Henan Cancer Hospital
Status RECRUITING
Cancer Type Sarcoma
Interventions Lenvatinib mesylate capsule
Locations (sample) Zhengzhou, Henan, China|34.75778,113.64861
Key Eligibility Criteria
Ages 10-70, both male and female. The Eastern Collaborative Oncology Group (ECOG) physical status score was 0-1. Subjects with amputation can be relaxed up to 2 points. The expected survival time was ≥3 months. Subjects with bone and soft tissue sarcomas with distant metastases or locally advanced disease who were not considered suitable for surgical treat…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →